Keywords
Cancer researchCytotoxic T cellTargeted therapyLigand (biochemistry)Radiation therapyAntigenMalignant cellsChemotherapyMedicineCancerCancer cellImmunologyChemistryReceptorInternal medicineIn vitroBiochemistry
Affiliated Institutions
Related Publications
Cancer immunotherapy using checkpoint blockade
The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Therapeutic antibodies that block the programmed death-1 (PD-1)–programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancer...
T cell receptor-dependent, antigen-specific stimulation of a murine T cell clone induces a transient, VLA protein-mediated binding to extracellular matrix
Abstract Upon Ag stimulation, an arsonate-specific murine T cell clone exhibited a rapid but transient increase in cell adhesion to collagen, fibronectin, and laminin. This incr...
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
Abstract Overexpression and enhanced activation of the epidermal growth factor receptor (EGFR) is frequently observed in human carcinomas. Inhibitors of EGFR signaling have show...
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use o...
Publication Info
- Year
- 2002
- Type
- review
- Volume
- 2
- Issue
- 10
- Pages
- 750-763
- Citations
- 1617
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
1617
OpenAlex
Cite This
Theresa M. Allen
(2002).
Ligand-targeted therapeutics in anticancer therapy.
Nature reviews. Cancer
, 2
(10)
, 750-763.
https://doi.org/10.1038/nrc903
Identifiers
- DOI
- 10.1038/nrc903